Figure 5. ADE of DENV3 infection at illness onset in infants with symptomatic primary DENV3 infections.

The most proximal pre-illness plasma sample from each infant with symptomatic primary DENV3 infection (n = 34) was diluted to achieve the estimated neutralizing capacity at illness onset and used in the ADE assay, as described in the Methods. Values are log₁₀ transformed DENV3 genome eqs/ml in cell culture supernatants at 72 h, mean±standard deviation of individual plasma samples from three independent experiments. Mean DENV3 genome eqs/ml and 95% CI are shown for each of the disease severity groups (mean [95% CI]). Closed squares, hospitalized infants with DHF; open triangles, hospitalized infants without DHF; open circles, nonhospitalized infants without DHF. ^a p<0.01 compared to virus alone; ^b p<0.01 compared to flavivirus seronegative plasma control. There were no significant differences among the disease severity groups (see Results).